The present invention relates to cancer immunotherapy. Conjugates and nanoparticles comprising active agents that can elicit a cancer specific immune response are provided. The conjugates comprise one or more targeting moieties that are connected to the active agents. Nanoparticles comprising the conjugates of the present invention are also provided to increase the delivery of the conjugates, and increase immunogenicity and lower toxicity.
